Novel Agent for Chronic GVHD Wins FDA Approval

Published Date: 19 Aug 2024

Axatilimab achieved a 75% response rate in patients with previously treated chronic GVHD

Read Full News

Latest News

HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503

News All Time

HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Dementia-like protein buildup found in pancreas cells before cancer develops

2.

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

3.

Survival rates for incurable larynx cancer investigated for first time

4.

NPM1-Mutated AML: Not All Treatments Are Equal

5.

Novel Agent for Chronic GVHD Wins FDA Approval


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot